Errata (DOI:10.1016/S1474-4422(08)70167-4);Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

The Lancet Neurology

Volumn 7, Issue 9, 2008, Pages 779-786

  Lannfelt, Lars ^a   Blennow, Kaj ^b   Zetterberg, Henrik ^b   Batsman, Stellan ^c   Ames, David ^d   Harrison, John ^e,h   Masters, Colin L ^d   Targum, Steve ^f   Bush, Ashley I ^d   Murdoch, Ross ^g   Wilson, Janet ^g   Ritchie, Craig W ^h  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Vårdcentralen Kalix   (Sweden)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Cogstate Ltd ^*  (United Kingdom)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g Prana Biotechnology   (Australia)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; COPPER; DONEPEZIL; GALANTAMINE; NOOTROPIC AGENT; PBT 2; PLACEBO; RIVASTIGMINE; UNCLASSIFIED DRUG; ZINC;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ARTICLE; BACKACHE; BIOCHEMISTRY; BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPPER BLOOD LEVEL; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EYE EXAMINATION; FALLING; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HACHINSKI SCORE; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NECK PAIN; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; SOMNOLENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; VITAL SIGN; ZINC BLOOD LEVEL;

EID: 48949098573     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70279-0     Document Type: Erratum

References (31)

1. O'Connor DW. Epidemiology in Dementia, 3rd edn. 2005 Burns, O'Brien and Ames. Hodder Arnold, London.
2. Ritchie C.W., Ames D., Clayton T., and Lai R. A meta-analysis of randomised trials for the efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer's disease. Am J Geriatr Psychiatry 12 (2004) 358-369
3. Kang J., Lemaire H.G., Unterbeck A., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 (1987) 733-736
4. McLean C.A., Cherny R.A., Fraser F.W., et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (1999) 860-866
5. Walsh D.M., and Selkoe D.J. Aβ oligomers-a decade of discovery. J Neurochem 101 (2007) 1172-1184
6. Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., and Koh J.Y. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 99 (2002) 7705-7710
7. Schlief M.L., Craig A.M., and Gitlin J.D. NMDA-receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 25 (2005) 239-246
8. Bush A.I., Pettingell W.H., Multhaup G., et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265 (1994) 1464-1467
9. Atwood C.S., Moir R.D., Huang X., et al. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273 (1998) 12817-12826
10. 2. J Biol Chem 277 (2002) 40302-40308
11. Cherny R.A., Atwood C.S., Xilinas M.E., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
12. Ritchie C.W., Bush A.I., Mackinnon A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
13. Adlard P.A., Cherny R.A., Finkelstein D.I., et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59 (2008) 43-55
14. Cummings J.L., Doody R., and Clark C. Disease-modifying therapies for Alzheimer's disease: challenges to early intervention. Neurology 69 (2007) 1622-1634
15. Folstein M.F., Folstein S.E., and McHugh P.R. Mini mental state-a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
16. Rosen W.G., Mohs R.C., and Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
17. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007) 734-746
18. Ritchie C.W., Bush A.I., and Masters C.L. Metal-protein attenuating compounds and Alzheimer's disease. Expert Opin Investig Drugs 13 (2004) 1585-1592
19. Albers J.W. Clioquinol. In: Berent S., and Albers J.W. (Eds). Neurobehavioral toxicology. Neuropsychological and neurological perspectives, vol 3. Central nervous system (2008), Taylor & Francis, London and New York 857-879
20. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
21. Hansson O., Zetterberg H., Vanmechelen E., et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 10.1016/j.neurobiolaging.2008.03.027 published online May 19.
22. Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., and Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?. Mol Chem Neuropathol 26 (1995) 231-245
23. Vanmechelen E., Vanderstichele H., Davidsson P., et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285 (2000) 49-52
24. Harrison J., Minassian S.L., Jenkins L., Black R.S., Koller M., and Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 64 (2007) 1323-1329
25. Committee for Medicinal Products for Human Use (2007). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias (Draft). http://www.emea.europa.eu/pdfs/human/ewp/055395endraft.pdf (accessed July 2007).
26. Aisen P.S., Saumier D., Briand R., et al. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67 (2006) 1757-1763
27. Blennow K., Zetterberg H., Minthon L., et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 419 (2007) 18-22
28. DeMattos R.B., Bales K.R., Parsadanian M., et al. Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81 (2002) 229-236
29. Li Q.X., Whyte S., Tanner J.E., Evin G., Beyreuther K., and Masters C.L. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 78 (1998) 461-469
30. Szlyk J., Myers L., Zhang Y.X., Wetzel L., and Shapiro R. Development and assessment of a Neuropsychological Battery to aid in predicting driving performance. J Rehabil Res Dev 39 (2002) 483-496
31. Salloway S., Mintzer J., Weiner M.F., and Cummings J.L. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement 4 (2008) 65-79